94 results on '"Villar, L.M."'
Search Results
2. Guía de laboratorio para el diagnóstico y seguimiento de pacientes con gammapatías monoclonales
- Author
-
Bravo García-Morato, M., Padilla-Merlano, B., Nozal, P., Espiño, M., Juárez, C., Villar, L.M., and López-Trascasa, M.
- Published
- 2016
- Full Text
- View/download PDF
3. The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands
- Author
-
Boscá, I., Magraner, M.J., Coret, F., Álvarez-Cermeño, J.C., Simó-Castelló, M., Villar, L.M., and Casanova, B.
- Published
- 2010
- Full Text
- View/download PDF
4. Genetic variability of hepatitis A virus isolates in Rio de Janeiro: implications for the vaccination of school children
- Author
-
Villar L.M., Lampe E., Meyer A., and Gaspar A.M.C.
- Subjects
Hepatitis A virus (HAV) ,PCR ,Molecular epidemiology ,Sero-epidemiology ,Vaccination ,Medicine (General) ,R5-920 ,Biology (General) ,QH301-705.5 - Abstract
The epidemiology of hepatitis A virus (HAV) infection is shifting from high to intermediate endemicity in Brazil, resulting in increased numbers of susceptible individuals and a greater potential for the emergence of outbreaks. Universal vaccination against HAV has been recommended for children, but updated sero-epidemiological data are necessary to analyze the level of natural immunity and to identify candidates for preventive measures. In addition, more molecular studies are necessary to characterize the genotypes involved in HAV infections and outbreaks. Sera from 299 school children (5-15 years old) and 25 school staff members, collected during an outbreak of HAV at a rural public school in June 2000, were tested for IgM and total anti-HAV antibodies (ELISA). Viral RNA was amplified by RT-PCR from anti-HAV IgM-positive sera and from 19 fecal samples. Direct nucleotide sequencing of the VP1/2A region was carried out on 18 PCR-positive samples. Acute HAV infection was detected by anti-HAV IgM in 93/299 children and in 3/25 adult staff members. The prevalence of total anti-HAV antibodies in IgM-negative children under 5 years of age was only 10.5%. HAV-RNA was detected in 46% IgM-positive serum samples and in 16% stool samples. Sequence analysis showed that half the isolates belonged to subgenotype IA and the other half to IB. On the basis of these data, mass vaccination against HAV is recommended without prevaccination screening, especially for children before they enter school, since nearly 90% of the children under 5 years were susceptible. Molecular characterization indicated the endemic circulation of specific HAV strains belonging to subgenotypes IA and IB.
- Published
- 2004
5. Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis
- Author
-
Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), European Commission, Picón, C., Tejeda-Velarde, A., Fernández-Velasco, J.I., Comabella, Manuel, Alvarez-Lafuente, R., Quintana, E., Sainz de la Maza, S., Monreal, E., Villarrubia, N., Álvarez-Cermeño, José Carlos, Dominguez-Mozo, M.I., Ramió-Torrentà, Lluís, Rodríguez-Martín, Eulalia, Roldán, E., Aladro, Yolanda, Medina, S., Espiño, Mercedes, Masjuán, J., Matute-Blanch, Clara, Muñoz-San Martín, M., Espejo, C., Guaza, Carmen, Muriel, Alfonso, Costa-Frossard, L., Villar, L.M., Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), European Commission, Picón, C., Tejeda-Velarde, A., Fernández-Velasco, J.I., Comabella, Manuel, Alvarez-Lafuente, R., Quintana, E., Sainz de la Maza, S., Monreal, E., Villarrubia, N., Álvarez-Cermeño, José Carlos, Dominguez-Mozo, M.I., Ramió-Torrentà, Lluís, Rodríguez-Martín, Eulalia, Roldán, E., Aladro, Yolanda, Medina, S., Espiño, Mercedes, Masjuán, J., Matute-Blanch, Clara, Muñoz-San Martín, M., Espejo, C., Guaza, Carmen, Muriel, Alfonso, Costa-Frossard, L., and Villar, L.M.
- Abstract
Patients with multiple sclerosis (MS) suffer with age an early immunosenescence process, which influence the treatment response and increase the risk of infections. We explored whether lipid-specific oligoclonal IgM bands (LS-OCMB) associated with highly inflammatory MS modify the immunological profile induced by age in MS. This cross-sectional study included 263 MS patients who were classified according to the presence (M+, n=72) and absence (M-, n=191) of LS-OCMB. CSF cellular subsets and molecules implicated in immunosenescence were explored. In M- patients, aging induced remarkable decreases in absolute CSF counts of CD4+ and CD8+ T lymphocytes, including Th1 and Th17 cells, and of B cells, including those secreting TNF-alpha. It also increased serum anti-CMV IgG antibody titers (indicative of immunosenescence) and CSF CHI3L1 levels (related to astrocyte activation). In contrast, M+ patients showed an age-associated increase of TIM-3 (a biomarker of T cell exhaustion) and increased values of CHI3L1, independently of age. Finally, in both groups, age induced an increase in CSF levels of PD-L1 (an inductor of T cell tolerance) and activin A (part of the senescence-associated secretome and related to inflammaging). These changes were independent of the disease duration. Finally, this resulted in augmented disability. In summary, all MS patients experience with age a modest induction of T-cell tolerance and an activation of the innate immunity, resulting in increased disability. Additionally, M- patients show clear decreases in CSF lymphocyte numbers, which could increase the risk of infections. Thus, age and immunological status are important for tailoring effective therapies in MS.
- Published
- 2021
6. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
- Author
-
Dominguez-Mozo, M.I., Pérez-Pérez, S., Villar, L.M., Oliver-Martos, Begoña, Villarrubia, N., Matesanz, F., Costa-Frossard, L., Pinto-Medel, María Jesús, García-Sánchez, María Isabel, Ortega-Madueño, Isabel, Lopez-Lozano, L., García-Martínez, A., Izquierdo, G., Fernández, Óscar, Álvarez-Cermeño, José Carlos, Arroyo, Rafael, Alvarez-Lafuente, R., Dominguez-Mozo, M.I., Pérez-Pérez, S., Villar, L.M., Oliver-Martos, Begoña, Villarrubia, N., Matesanz, F., Costa-Frossard, L., Pinto-Medel, María Jesús, García-Sánchez, María Isabel, Ortega-Madueño, Isabel, Lopez-Lozano, L., García-Martínez, A., Izquierdo, G., Fernández, Óscar, Álvarez-Cermeño, José Carlos, Arroyo, Rafael, and Alvarez-Lafuente, R.
- Abstract
There are an increasing number of treatments available for multiple sclerosis (MS). The early identification of optimal responders to individual treatments is important to achieve individualized therapy. With this aim, we performed a multicenter retrospective longitudinal study including 186 MS patients treated with natalizumab who were followed for 2 years. We analyzed the following variables at recruitment: sex, current age, age at disease onset, disease duration, EDSS, number of T2 and Gd + lesions, IgG and IgM oligoclonal bands, HLA class II (DR, DRB, DQA, DQB, and DRB1*15:01), IgG and IgM antibody titers against human herpesvirus 6 (HHV-6) and the antibody response to Epstein–Barr virus (EBV) through the measurement of the anti-EBNA-1 and anti-VCA IgG titers, in relation to clinical response (no relapses or disability progression), and to NEDA-3 (no evidence of disease activity in terms of clinical response and no changes in MRI scans either) after 2-years follow-up. Baseline EDSS score, baseline EBNA-1 IgG titers and percentage change of HHV6 IgG titers between baseline and 6 month visits were significantly different in clinical responders and in NEDA-3 status (all of them remained significant in the multivariate analysis). We identified three variables for the early identification of natalizumab optimal responders in a rapid and cost-effective approach.
- Published
- 2020
7. NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients
- Author
-
Malhotra, S., Costa, C., Eixarch, H., Keller, C.W., Amman, L., Martínez-Banaclocha, H., Midaglia, L., Sarró, E., Machín-Díaz, Isabel, Villar, L.M., Triviño, J.C., Oliver-Martos, Begoña, Parladé, L.N., Calvo-Barreiro, L., Matesanz, F., Vandenbroeck, K., Urcelay, E., Martínez-Ginés, M.L., Tejeda-Velarde, A., Fissolo, N., Castilló, J., Sanchez, A., Robertson, A.A.B., Clemente, Diego, Prinz, M., Pelegrín, Pablo, Lünemann, J.D., Espejo, C., Montalbán, Xavier, Comabella, Manuel, Malhotra, S., Costa, C., Eixarch, H., Keller, C.W., Amman, L., Martínez-Banaclocha, H., Midaglia, L., Sarró, E., Machín-Díaz, Isabel, Villar, L.M., Triviño, J.C., Oliver-Martos, Begoña, Parladé, L.N., Calvo-Barreiro, L., Matesanz, F., Vandenbroeck, K., Urcelay, E., Martínez-Ginés, M.L., Tejeda-Velarde, A., Fissolo, N., Castilló, J., Sanchez, A., Robertson, A.A.B., Clemente, Diego, Prinz, M., Pelegrín, Pablo, Lünemann, J.D., Espejo, C., Montalbán, Xavier, and Comabella, Manuel
- Abstract
Primary progressive multiple sclerosis is a poorly understood disease entity with no specific prognostic biomarkers and scarce therapeutic options. We aimed to identify disease activity biomarkers in multiple sclerosis by performing an RNA sequencing approach in peripheral blood mononuclear cells from a discovery cohort of 44 untreated patients with multiple sclerosis belonging to different clinical forms and activity phases of the disease, and 12 healthy control subjects. A validation cohort of 58 patients with multiple sclerosis and 26 healthy control subjects was included in the study to replicate the RNA sequencing findings. The RNA sequencing revealed an interleukin 1 beta (IL1B) signature in patients with primary progressive multiple sclerosis. Subsequent immunophenotyping pointed to blood monocytes as responsible for the IL1B signature observed in this group of patients. Functional experiments at baseline measuring apoptosis-associated speck-like protein containing a CARD (ASC) speck formation showed that the NOD-leucine rich repeat and pyrin containing protein 3 (NLRP3) inflammasome was overactive in monocytes from patients with primary progressive multiple sclerosis, and canonical NLRP3 inflammasome activation with a combination of ATP plus lipopolysaccharide was associated with increased IL1B production in this group of patients. Primary progressive multiple sclerosis patients with high IL1B gene expression levels in peripheral blood mononuclear cells progressed significantly faster compared to patients with low IL1B levels based on the time to reach an EDSS of 6.0 and the Multiple Sclerosis Severity Score. In agreement with peripheral blood findings, both NLRP3 and IL1B expression in brain tissue from patients with primary progressive multiple sclerosis was mainly restricted to cells of myeloid lineage. Treatment of mice with a specific NLRP3 inflammasome inhibitor attenuated established experimental autoimmune encephalomyelitis disease severity and impro
- Published
- 2020
8. Hepatitis A virus in environmental water samples from the Amazon Basin
- Author
-
De Paula, V.S., Diniz-Mendes, L., Villar, L.M., Luz, S.L.B., Silva, L.A., Jesus, M.S., da Silva, N.M.V.S., and Gaspar, A.M.C.
- Published
- 2007
- Full Text
- View/download PDF
9. Thermal diffusivity measurements in porous ceramics by photothermal methods
- Author
-
Sánchez-Lavega, A., Salazar, A., Ocariz, A., Pottier, L., Gomez, E., Villar, L.M., and Macho, E.
- Published
- 1997
- Full Text
- View/download PDF
10. Oral gut microbiota manipulation by antibiotics and probiotics influences neuroimmune responses in a progressive model of multiple sclerosis
- Author
-
Mestre, Leyre, Carrillo-Salinas, F. J., Mecha, Miriam, Feliú, Ana, Espejo, Carmen, Villar, L.M., Guaza, Carmen, and Red Española de Esclerosis Múltiple
- Subjects
Myelin diseases ,Immune Function ,Microglial cells - Abstract
On the last decade, cumulative evidence reported a relationship between gut microbiota and MS. Both gut microbiota eradication and probiotic administration attenuated the clinical severity of autoimmune models of MS (EAE). However, an unresolved question is to what extent manipulations of gut microbiota affect the course of the disease. Particularly, the relevance of gut microbiota on the progressive forms of MS is a field little explored. Here, we addressed how gut microbiota manipulation by antibiotics and/or probiotics influences the establishment of clinical symptomatology in the TMEV-IDD model of progressive MS. Experimental groups are showed in the scheme below. Main results reveal that motor disability can be prevented in TMEV-mice treated with antibiotic mix (ABX) during the presyntomatic stage (55-70dpi); the attenuation of motor deficits was maintained in mice treated with ABX until day 85dpi (symptomatic phase). The beneficial effect was less powerful in ABX-mice that stopped the treatment at day 70pi and gut microbiota started recolonization in the presence of the probiotic (Vivomixx) for 15 days. Accordingly, the increased regulatory CD39+ T and CD5CD1high B cells in the CNS of ABX- treated mice was reverted after ABX cessation an probiotic administration. Likewise, the proinflammatory cytokines IL-1β and TNF-α increased and the anti-inflammatory cytokines IL-4 and IL-10 decreased in the CNS of TMEV mice that interrupted oral ABX and received Vivomixx. In this scenario, microglia also undergoes morphological changes upon the different microbiota challenges. Mainly, cells show transitioning morphology from thin cell bodies with numerous branched extensions to round, amoeboid cells with fewer branches in TMEV-ABX mice increasing the percentage of Iba-1 staining area versus TMEV mice. Astrocytes also show morphological changes under microbiota manipulation. We also addressed the therapeutic effect of oral Vivomixx on the symptomatic stage. Similarly to ABX, the probiotic treatment improves motor disability of TMEV-mice; however, the underlying mechanisms were different: Thus, regulatory B cells acquired more prominence and microglial cells spread more branches than observed in the CNS of ABX-TMEV-mice. Our results support the relevance of the gut microbiota-CNS axis on neurodegenerative diseases particularly, on the progressive forms of MS., This work was supported by the Red Española de Esclerosis Múltiple (REEM: RD16/0015/0021) sponsored by the Fondo de Investigación Sanitaria (FIS).
- Published
- 2019
11. Detection of hepatitis A virus RNA in serum during the window period of infection
- Author
-
de Paula, V.S, Villar, L.M, Morais, L.M, Lewis-Ximenez, L.L, Niel, C, and Gaspar, A.M.C
- Published
- 2004
- Full Text
- View/download PDF
12. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis
- Author
-
Bridel, C. (Claire), Van Wieringen, W.N. (Wessel N.), Zetterberg, H. (Henrik), Tijms, B.M. (Betty M.), Teunissen, C.E. (Charlotte), Álvarez-Cermeño, J.C. (José C), Andreasson, U. (Ulf), Axelsson, M. (Markus), Bäckström, D.C. (David C.), Bartos, A. (Ales), Bjerke, M. (Maria), Blennow, K. (Kaj), Boxer, A.L. (Adam), Brundin, L. (Lou), Burman, J. (Joachim), Christensen, T. (Tove), Fialová, L. (Lenká), Forsgren, L. (Lars), Frederiksen, H., Gisslén, M. (Magnus), Gray, E. (Elizabeth), Gunnarsson, M. (Martin), Hall, S. (Sara), Hansson, O. (Oskar), Herbert, M.K. (Megan K.), Jakobsson, J. (Joel), Jessen-Krut, J. (Jan), Janelidze, S. (Shorena), Johannsson, G., Jonsson, M. (Michael), Kappos, L. (Ludwig), Khademi, M. (Mohsen), Khalil, M. (Michael), Kuhle, J. (Jens), Landén, M. (Mikael), Leinonen, V. (Ville), Logroscino, G. (Giancarlo), Lu, C.-H. (Ching-Hua), Lycke, J. (Jan), Magdalinou, N. (Nadia), Malaspina, A. (Andrea), Mattsson, N. (Niklas), Meeter, L.H.H. (Lieke), Mehta, S.R. (Sanjay R.), Modvig, S. (Signe), Olsson, T., Paterson, R.W. (Ross W.), Pérez-Santiago, J. (Josué), Piehl, F. (Fredrik), Pijnenburg, Y.A.L. (Yolande), Pyykkö, O.T. (Okko T.), Ragnarsson, O. (Oskar), Rojas, J.C. (Julio C.), Romme Christensen, J. (Jeppe), Sandberg, L. (Linda), Scherling, C.S. (Carole S.), Schott, J.M. (Jonathan M.), Sellebjerg, F. (Finn), Simone, I.L. (Isabella L.), Skillbäck, T. (Tobias), Stilund, M. (Morten), Sundström, P. (Peter), Svenningsson, A. (Anders), Tortelli, R. (Rosanna), Tortorella, C. (Carla), Trentini, A. (Alessandro), Troiano, M. (Maria), Turner, M.R. (Martin R.), Swieten, J.C. (John) van, Vågberg, M. (Mattias), Verbeek, M.M. (Marcel), Villar, L.M. (Luisa María), Visser, P. (Pim), Wallin, A. (Anders), Weiss, A. (Andreas), Wikkelsø, C. (Carsten), Wild, E.J. (Edward J.), Bridel, C. (Claire), Van Wieringen, W.N. (Wessel N.), Zetterberg, H. (Henrik), Tijms, B.M. (Betty M.), Teunissen, C.E. (Charlotte), Álvarez-Cermeño, J.C. (José C), Andreasson, U. (Ulf), Axelsson, M. (Markus), Bäckström, D.C. (David C.), Bartos, A. (Ales), Bjerke, M. (Maria), Blennow, K. (Kaj), Boxer, A.L. (Adam), Brundin, L. (Lou), Burman, J. (Joachim), Christensen, T. (Tove), Fialová, L. (Lenká), Forsgren, L. (Lars), Frederiksen, H., Gisslén, M. (Magnus), Gray, E. (Elizabeth), Gunnarsson, M. (Martin), Hall, S. (Sara), Hansson, O. (Oskar), Herbert, M.K. (Megan K.), Jakobsson, J. (Joel), Jessen-Krut, J. (Jan), Janelidze, S. (Shorena), Johannsson, G., Jonsson, M. (Michael), Kappos, L. (Ludwig), Khademi, M. (Mohsen), Khalil, M. (Michael), Kuhle, J. (Jens), Landén, M. (Mikael), Leinonen, V. (Ville), Logroscino, G. (Giancarlo), Lu, C.-H. (Ching-Hua), Lycke, J. (Jan), Magdalinou, N. (Nadia), Malaspina, A. (Andrea), Mattsson, N. (Niklas), Meeter, L.H.H. (Lieke), Mehta, S.R. (Sanjay R.), Modvig, S. (Signe), Olsson, T., Paterson, R.W. (Ross W.), Pérez-Santiago, J. (Josué), Piehl, F. (Fredrik), Pijnenburg, Y.A.L. (Yolande), Pyykkö, O.T. (Okko T.), Ragnarsson, O. (Oskar), Rojas, J.C. (Julio C.), Romme Christensen, J. (Jeppe), Sandberg, L. (Linda), Scherling, C.S. (Carole S.), Schott, J.M. (Jonathan M.), Sellebjerg, F. (Finn), Simone, I.L. (Isabella L.), Skillbäck, T. (Tobias), Stilund, M. (Morten), Sundström, P. (Peter), Svenningsson, A. (Anders), Tortelli, R. (Rosanna), Tortorella, C. (Carla), Trentini, A. (Alessandro), Troiano, M. (Maria), Turner, M.R. (Martin R.), Swieten, J.C. (John) van, Vågberg, M. (Mattias), Verbeek, M.M. (Marcel), Villar, L.M. (Luisa María), Visser, P. (Pim), Wallin, A. (Anders), Weiss, A. (Andreas), Wikkelsø, C. (Carsten), and Wild, E.J. (Edward J.)
- Abstract
Importance: Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number of neurological conditions compared with healthy controls (HC) and is a candidate biomarker for neuroaxonal damage. The influence of age and sex is largely unknown, and levels across neurological disorders have not been compared systematically to date. Objectives: To assess the associations of age, sex, and diagnosis with NfL in CSF (cNfL) and to evaluate its potential in discriminating clinically similar conditions. Data Sources: PubMed was searched for studies published between January 1, 2006, and January 1, 2016, reporting cNfL levels (using the search terms neurofilament light and cerebrospinal fluid) in neurological or psychiatric conditions and/or in HC. Study Selection: Studies reporting NfL levels measured in lumbar CSF using a commercially available immunoassay, as well as age and sex. Data Extraction and Synthesis: Individual-level data were requested from study authors. Generalized linear mixed-effects models were used to estimate the fixed effects of age, sex, and diagnosis on log-transformed NfL levels, with cohort of origin modeled as a random intercept. Main Outcome and Measure: The cNfL levels adjusted for age and sex across diagnoses. Results: Data were collected for 10059 individuals (mean [SD] age, 59.7 [18.8] years; 54.1% female). Thirty-five diagnoses were identified, including inflammatory diseases of the central nervous system (n = 2795), dementias and predementia stages (n = 4284), parkinsonian disorders (n = 984), and HC (n = 1332). The cNfL was elevated compared with HC in a majority of neurological conditions studied. Highest levels were observed in cognitively impaired HIV-positive individuals (iHIV), amyotrophic lateral sclerosis, frontotemporal dementia (FTD), and Huntington disease. In 33.3% of diagnoses, including HC, multiple sclerosis, Alzheimer disease (AD), and Parkinson disease (PD), cNfL was higher in men than women. The cNfL incr
- Published
- 2019
- Full Text
- View/download PDF
13. Kappa free light chains is a valid tool in the diagnostics of MS: a large multicenter study
- Author
-
Ayşe, Altıntaş, Leurs, C.E.; Twaalfhoven, H.A.M.; Lissenberg-Witte, B.I.; van Pesch, V.; Dujmovic, I.; Drulovic, J.; Castellazzi, M.; Bellini, T.; Pugliatti, M.; Kuhle, J.; Villar, L.M.; Alvarez-Cermeño, J.C.; Alvarez-Lafuente, R.; Hegen, H.; Deisenhammer, F.; Walchhofer, L.M.; Thouvenot, E.; Comabella, M.; Montalban, X.; Vécsei, L.; Rajda, C.; Galimberti, D.; Scarpini, E.; Rejdak, K.; Frederiksen, J.L.; Pihl-Jensen, G.; Jensen, P.E.H.; Khalil, M.; Voortman, M.M.; Fazekas, F.; Saiz, A.; La Puma, D.; Vercammen, M.; Vanopdenbosch, L.; Uitdehaag, B.M.J.; Killestein, J.; Bridel, C.; Teunissen, C., School of Medicine, Department of Neurology, Ayşe, Altıntaş, Leurs, C.E.; Twaalfhoven, H.A.M.; Lissenberg-Witte, B.I.; van Pesch, V.; Dujmovic, I.; Drulovic, J.; Castellazzi, M.; Bellini, T.; Pugliatti, M.; Kuhle, J.; Villar, L.M.; Alvarez-Cermeño, J.C.; Alvarez-Lafuente, R.; Hegen, H.; Deisenhammer, F.; Walchhofer, L.M.; Thouvenot, E.; Comabella, M.; Montalban, X.; Vécsei, L.; Rajda, C.; Galimberti, D.; Scarpini, E.; Rejdak, K.; Frederiksen, J.L.; Pihl-Jensen, G.; Jensen, P.E.H.; Khalil, M.; Voortman, M.M.; Fazekas, F.; Saiz, A.; La Puma, D.; Vercammen, M.; Vanopdenbosch, L.; Uitdehaag, B.M.J.; Killestein, J.; Bridel, C.; Teunissen, C., School of Medicine, and Department of Neurology
- Abstract
Objective: to validate kappa free light chain (KFLC) and lambda free light chain (LFLC) indices as a diagnostic biomarker in multiple sclerosis (MS). Methods: we performed a multicenter study including 745 patients from 18 centers (219 controls and 526 clinically isolated syndrome (CIS)/MS patients) with a known oligoclonal IgG band (OCB) status. KFLC and LFLC were measured in paired cerebrospinal fluid (CSF) and serum samples. Gaussian mixture modeling was used to define a cut-off for KFLC and LFLC indexes. Results: the cut-off for the KFLC index was 6.6 (95% confidence interval (CI) = 5.2–138.1). The cut-off for the LFLC index was 6.9 (95% CI = 4.5–22.2). For CIS/MS patients, sensitivity of the KFLC index (0.88; 95% CI = 0.85–0.90) was higher than OCB (0.82; 95%CI = 0.79–0.85; p < 0.001), but specificity (0.83; 95% CI = 0.78–0.88) was lower (OCB = 0.92; 95% CI = 0.89–0.96; p < 0.001). Both sensitivity and specificity for the LFLC index were lower than OCB. Conclusion: compared with OCB, the KFLC index is more sensitive but less specific for diagnosing CIS/MS. Lacking an elevated KFLC index is more powerful for excluding MS compared with OCB but the latter is more important for ruling in a diagnosis of CIS/MS., NA
- Published
- 2019
14. Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine
- Author
-
Hernández-Breijo, B., primary, Jurado, T., additional, Rodríguez-Martín, E., additional, Martínez-Feito, A., additional, Plasencia-Rodríguez, C., additional, Balsa, A., additional, Alonso-Pacheco, M.L., additional, Villar, L.M., additional, Herranz-Pinto, P., additional, and Pascual-Salcedo, D., additional
- Published
- 2018
- Full Text
- View/download PDF
15. Gut dysbiosis and neuroimmune responses to brain infection with Theiler’s murine encephalomyelitis virus
- Author
-
Red Española de Esclerosis Múltiple, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Carrillo-Salinas, F. J., Mestre, Leyre, Mecha, Miriam, Feliú, Ana, Campo, Rosa del, Villarrubia, N., Montalbán, Xavier, Álvarez-Cermeño, José Carlos, Villar, L.M., Red Española de Esclerosis Múltiple, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Carrillo-Salinas, F. J., Mestre, Leyre, Mecha, Miriam, Feliú, Ana, Campo, Rosa del, Villarrubia, N., Montalbán, Xavier, Álvarez-Cermeño, José Carlos, and Villar, L.M.
- Abstract
Recent studies have begun to point out the contribution of microbiota to multiple sclerosis (MS) pathogenesis. Theiler’s murine encephalomyelitis virus induced demyelinating disease (TMEV-IDD) is a model of progressive MS. Here, we first analyze the effect of intracerebral infection with TMEV on commensal microbiota and secondly, whether the early microbiota depletion influences the immune responses to TMEV on the acute phase (14 dpi) and its impact on the chronic phase (85 dpi). The intracranial inoculation of TMEV was associated with a moderate dysbiosis. The oral administration of antibiotics (ABX) of broad spectrum modified neuroimmune responses to TMEV dampening brain CD4+ and CD8+ T infiltration during the acute phase. The expression of cytokines, chemokines and VP2 capsid protein was enhanced and accompanied by clusters of activated microglia disseminated throughout the brain. Furthermore, ABX treated mice displayed lower levels of CD4+ and CD8+T cells in cervical and mesenteric lymph nodes. Increased mortality to TMEV was observed after ABX cessation at day 28pi. On the chronic phase, mice that survived after ABX withdrawal and recovered microbiota diversity showed subtle changes in brain cell infiltrates, microglia and gene expression of cytokines. Accordingly, the surviving mice of the group ABX-TMEV displayed similar disease severity than TMEV mice.
- Published
- 2017
16. Applicability of Dried Blood Samples for Hepatitis C Virus Detection and Quantification
- Author
-
Villar, L.M., primary, Marques, B.L.C., additional, Espírito-Santos, M.P., additional, Marques, V.A., additional, Villela-Nogueira, C.A., additional, Lewis-Ximenez, L.L., additional, and Lampe, E., additional
- Published
- 2016
- Full Text
- View/download PDF
17. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice
- Author
-
Espiño, M., primary, Abraira, V., additional, Arroyo, R., additional, Bau, L., additional, Cámara, C., additional, Campos-Ruiz, L., additional, Casanova, B., additional, Espejo, C., additional, Fernández, O., additional, García-Merino, A., additional, García-Sánchez, M.I., additional, Gómez, M., additional, Gosis, A., additional, Izquierdo, G., additional, Meca, J., additional, Montalban, X., additional, Morandeira, F., additional, Olascoaga, J., additional, Prada, A., additional, Quintana, E., additional, Ramió-Torrentà, Ll., additional, Rodríguez-Antigüedad, A., additional, Salgado, G., additional, Santiago, J.L., additional, Sarasola, E., additional, Simó-Castelló, M., additional, Alvarez-Cermeño, J.C., additional, and Villar, L.M., additional
- Published
- 2015
- Full Text
- View/download PDF
18. Neurofilament ELISA validation
- Author
-
Petzold, A. Altintas, A. Andreoni, L. Bartos, A. Berthele, A. Blankenstein, M.A. Buee, L. Castellazzi, M. Cepok, S. Comabella, M. Constantinescu, C.S. Deisenhammer, F. Deniz, G. Erten, G. Espiño, M. Fainardi, E. Franciotta, D. Freedman, M.S. Giedraitis, V. Gilhus, N.E. Giovannoni, G. Glabinski, A. Grieb, P. Hartung, H.-P. Hemmer, B. Herukka, S.-K. Hintzen, R. Ingelsson, M. Jackson, S. Jacobsen, S. Jafari, N. Jalosinski, M. Jarius, S. Kapaki, E. Kieseier, B.C. Koel-Simmelink, M.J.A. Kornhuber, J. Kuhle, J. Kurzepa, J. Lalive, P.H. Lannfelt, L. Lehmensiek, V. Lewczuk, P. Livrea, P. Marnetto, F. Martino, D. Menge, T. Norgren, N. Papuć, E. Paraskevas, G.P. Pirttilä, T. Rajda, C. Rejdak, K. Ricny, J. Ripova, D. Rosengren, L. Ruggieri, M. Schraen, S. Shaw, G. Sindic, C. Siva, A. Stigbrand, T. Stonebridge, I. Topcular, B. Trojano, M. Tumani, H. Twaalfhoven, H.A.M. Vécsei, L. Van Pesch, V. Vanderstichele, H. Vedeler, C. Verbeek, M.M. Villar, L.M. Weissert, R. Wildemann, B. Yang, C. Yao, K. Teunissen, C.E.
- Abstract
Background: Neurofilament proteins (Nf) are highly specific biomarkers for neuronal death and axonal degeneration. As these markers become more widely used, an inter-laboratory validation study is required to identify assay criteria for high quality performance. Methods: The UmanDiagnostics NF-light ®enzyme-linked immunoabsorbent assays (ELISA) for the neurofilament light chain (NfL, 68 kDa) was used to test the intra-assay and inter-laboratory coefficient of variation (CV) between 35 laboratories worldwide on 15 cerebrospinal fluid (CSF) samples. Critical factors, such as sample transport and storage, analytical delays, reaction temperature and time, the laboratories' accuracy and preparation of standards were documented and used for the statistical analyses. Results: The intra-laboratory CV averaged 3.3% and the inter-laboratory CV 59%. The results from the test laboratories correlated with those from the reference laboratory (R = 0.60, p < 0.0001). Correcting for critical factors improved the strength of the correlation. Differences in the accuracy of standard preparation were identified as the most critical factor. Correcting for the error introduced by variation in the protein standards improved the correlation to R = 0.98, p < 0.0001 with an averaged inter-laboratory CV of 14%. The corrected overall inter-rater agreement was subtantial (0.6) according to Fleiss' multi-rater kappa and Gwet's AC1 statistics. Conclusion: This multi-center validation study identified the lack of preparation of accurate and consistent protein standards as the main reason for a poor inter-laboratory CV. This issue is also relevant to other protein biomarkers based on this type of assay and will need to be solved in order to achieve an acceptable level of analytical accuracy. The raw data of this study is available online. © 2009 Elsevier B.V.
- Published
- 2010
19. Sperm-associated antigen 16 is a novel target of the humoral autoimmune response in multiple sclerosis
- Author
-
Bock, L. de, Somers, K., Fraussen, J., Hendriks, J.J., Horssen, J. van, Rouwette, M., Hellings, N., Villar, L.M., Alvarez-Cermeno, J.C., Espino, M., Hupperts, R., Jongen, P., Damoiseaux, J., Verbeek, M.M., Deyn, P.P. de, D'Hooghe, M., Wijmeersch, B. Van, Stinissen, P., Somers, V., Bock, L. de, Somers, K., Fraussen, J., Hendriks, J.J., Horssen, J. van, Rouwette, M., Hellings, N., Villar, L.M., Alvarez-Cermeno, J.C., Espino, M., Hupperts, R., Jongen, P., Damoiseaux, J., Verbeek, M.M., Deyn, P.P. de, D'Hooghe, M., Wijmeersch, B. Van, Stinissen, P., and Somers, V.
- Abstract
Item does not contain fulltext, We have previously identified eight novel autoantibody targets in the cerebrospinal fluid of multiple sclerosis (MS) patients, including sperm-associated Ag 16 (SPAG16). In the current study, we further investigated the autoantibody response against SPAG16-a protein with unknown function in the CNS-and its expression in MS pathology. Using isoelectric focusing, we detected SPAG16-specific oligoclonal bands in the cerebrospinal fluid of 5 of 23 MS patients (22%). Analysis of the anti-SPAG16 Ab reactivity in the plasma of a total of 531 donors using ELISA demonstrated significantly elevated anti-SPAG16 Ab levels (p = 0.002) in 32 of 153 MS patients (21%) compared with all other control groups with 95% specificity for the disease. To investigate the pathologic relevance of anti-SPAG16 Abs in vivo, anti-SPAG16 Abs were injected in mice with experimental autoimmune encephalomyelitis, resulting in a significant disease exacerbation. Finally, we demonstrated a consistent upregulation of SPAG16 in MS brain and experimental autoimmune encephalomyelitis spinal cord lesions, more specifically in reactive astrocytes. We conclude that SPAG16 is a novel autoantibody target in a subgroup of MS patients and in combination with other diagnostic criteria, elevated levels of anti-SPAG16 Abs could be used as a biomarker for diagnosis. Furthermore, the pathologic relevance of anti-SPAG16 Abs was shown in vivo.
- Published
- 2014
20. Regulatory lymphocytes are key factors in mhc-independent resistance to EAE
- Author
-
Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Ministerio de Ciencia e Innovación (España), Generalitat de Catalunya, Red Española de Esclerosis Múltiple, Marín, N., Mecha, Miriam, Espejo, Carmen, Mestre, Leyre, Eixarch, H., Montalbán, Xavier, Álvarez-Cermeño, José Carlos, Guaza, Carmen, Villar, L.M., Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Ministerio de Ciencia e Innovación (España), Generalitat de Catalunya, Red Española de Esclerosis Múltiple, Marín, N., Mecha, Miriam, Espejo, Carmen, Mestre, Leyre, Eixarch, H., Montalbán, Xavier, Álvarez-Cermeño, José Carlos, Guaza, Carmen, and Villar, L.M.
- Abstract
[Background and Objectives] Resistant and susceptible mouse strains to experimental autoimmune encephalomyelitis (EAE), an inducible demyelinating experimental disease serving as animal model for multiple sclerosis, have been described. We aimed to explore MHC-independent mechanisms inducing resistance to EAE., [Methods] For EAE induction, female C57BL/6 (susceptible strain) and CD1 (resistant outbred strain showing heterogeneous MHC antigens) mice were immunized with the 35-55 peptide of myelin oligodendrocyte glycoprotein (MOG35-55). We studied T cell proliferation, regulatory and effector cell subpopulations, intracellular and serum cytokine patterns, and titers of anti-MOG serum antibodies., [Results] Upon immunization with MOG35-55, T lymphocytes from susceptible mice but not that of resistant strain were capable of proliferating when stimulated with MOG35-55. Accordingly, resistant mice experienced a rise in regulatory B cells (P = 0.001) and, to a lower extent, in regulatory T cells (P = 0.02) compared with C57BL/6 susceptible mice. As a consequence, MOG35-55-immunized C57BL/6 mice showed higher percentages of CD4+ T cells producing both IFN-gamma (P = 0.02) and IL-17 (P = 0.009) and higher serum levels of IL-17 (P = 0.04) than resistant mice., [Conclusions] Expansion of regulatory B and T cells contributes to the induction of resistance to EAE by an MHC-independent mechanism. © 2014 Nieves Marín et al.
- Published
- 2014
21. Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome
- Author
-
Rouwette, M., Somers, K., Govarts, C., Deyn, P.P. de, Hupperts, R., Van Wijmeersch, B., de Jong, B.A., Verbeek, M.M., Van Pesch, V., Sindic, C., Villar, L.M., Alvarez-Cermeno, J.C., Stinissen, P., Somers, V., Rouwette, M., Somers, K., Govarts, C., Deyn, P.P. de, Hupperts, R., Van Wijmeersch, B., de Jong, B.A., Verbeek, M.M., Van Pesch, V., Sindic, C., Villar, L.M., Alvarez-Cermeno, J.C., Stinissen, P., and Somers, V.
- Abstract
Item does not contain fulltext, Limited information is available on the identity of antigens targeted by antibodies present in cerebrospinal fluid (CSF) of patients with clinically isolated syndrome (CIS). The aim of this study was to identify novel antigens for CIS and investigate their prognostic potential to predict conversion to multiple sclerosis (MS). We applied serological antigen selection (SAS) to identify antigens interacting with antibodies present in the pooled CSF from four CIS patients, who developed MS. Antibody reactivity towards CIS antigens identified by SAS was tested in CSF and serum from patients with CIS (n = 123/n = 108), MS (n = 65/n = 44), and other (inflammatory) neurological diseases (n = 75/n = 38) as well as in healthy control sera (n = 44). Using SAS, a panel of six novel CIS candidate antigens was identified. CSF antibody reactivity was detected in both CIS and relapsing-remitting (RR) MS. Serum reactivity was significantly increased in CIS and RR-MS as compared with controls (p = 0.03). For two antigens, the frequency of antibody-positive patients was higher in CIS patients who converted to MS as compared with CIS patients without conversion. We identified novel CIS antigens to which antibody reactivity was primarily detected in CIS and RR-MS as compared to controls. Possible prognostic potential could be demonstrated for two antigens.
- Published
- 2012
22. THU-260 - Applicability of Dried Blood Samples for Hepatitis C Virus Detection and Quantification
- Author
-
Villar, L.M., Marques, B.L.C., Espírito-Santos, M.P., Marques, V.A., Villela-Nogueira, C.A., Lewis-Ximenez, L.L., and Lampe, E.
- Published
- 2016
- Full Text
- View/download PDF
23. Investigación sobre la presencia de antibióticos en la leche en la región sur de España
- Author
-
López Giménez, R., Pozo Lora, R., Herrera Marteache, A., Polo Villar, L.M., Iglesias Pérez, J., Jodral Villarejo, M., López Giménez, R., Pozo Lora, R., Herrera Marteache, A., Polo Villar, L.M., Iglesias Pérez, J., and Jodral Villarejo, M.
- Abstract
The presence of Penicilin, Streptomicine, Tetraciclines, Bacitracine, Neomicine and Kanamicine has been investigated in 1.346 samples of natural mil from the following provinces in the Southern region of Spain: Córdoba, Jaén, Granada, Málaga, Cádiz, Huelva and Sevilla. The microbiological tests performed were: a) detection of non specific inhibiting substances by the reduction of methylene blue test (Frank, 1965) and b) Jaquet and Stee"s (1952) cavities method for the detection of antibiotic substances indicated with sensitive germs. The germs used were: Sarcina Lutea (Núm. 9341 of American Collection of Culture Types, ATCC), for the Penicilin; Bacillus Subtilis (ATCC 6633), for the Streptomicine; Bacillus Cereus var. Mycoides (ATCC; 11778), for Tetraciclines; Sarcina Subflava (ATCC 7468), for the Bacitracine, and Staphilococcus Epidermis (ATCC, 12228), for the Neomicine, and Staphilococcus Aureus (ATCC, 6538-P for the Kanamicine, For each microbiological test of antibiotic detection studied, the fines of regression and the minimal detectable limits were obtained experimentally. According to the FAO/OMS mixed Comittee (1970), antibiotics should be used in such away that residues can not be detected in foods for human consumption; snd the Spanish Alimentary Code prohibits the sale and use of foods containing antibiotics. The levels of contarnination by no specific inhibiting substances is alarmingly high since it contained in 32"62 per 100 of the samples of milk analysed. Penicilin was detected in 1"19 per 100 of the samples, Streptomicine in 1.11 per 100, Tetraciclines in 1.04 per 100, Bacitracine in 9.8 per 100, Kanamicine in 0.30 per 100, and Neomicine in 1.04 per 100. Of the 1.346 milk samples analysed, 11.66 per 100 contained one or more antibiotic. In the province of Córdoba 25.87 per 100 of the milk samples contained antibiotics; in that of Jaén, 8.46 per 100; in Seville, 6.50 per 100; in Cádiz, 5 per 100; in Granada, 4 per 100, and in the province of Malaga, 2, Se ha investigado la presencia de penicilina, estreptomicina, tetraciclinas, ba¬citracina, neomicina y kanamicina en 1346 muestras, de leche natural, procedentes de diferentes zonas de las siguientes provincias de la región sur de España: Córdoba, Jaén, Granada, Málaga, Cádiz, Huelva y Sevilla. Las pruebas microbiológicas han sido: a) detección de sustancias inhibidoras inespecíficas por la prueba de reducción del azul de metileno (Frank, 1965) y b) método de las cavidades de Jacquet y Steeg (1952) para la detección de las surtan cias antibióticas indicadas con gérmenes sensiblesios gérmenes sensibles utilizados han sido: para la la penicilina, la Sarcina lutea (núm. 9341 de la Colección Americana de cultivos tipo, ATCC); para la estreptomicina, el Bacillus subtilis (ATCC 6633); para las tetraciclinas, el Bacillus cereus var mycoides (ATCC 11778); para la bacitracina, la Sarcina subflava (ATCC 7468); para la neomicina, el Staphilococcus epidermis (ATCC 12228); y para la kanamicina, el Staphylococcus aureus (ATCC 6538-P). Se han obtenido experimentalmente, para cada prueba microbiológica de detección específica de los antibióticos estudiados, las líneas de regresión y los límites mínimos detectables. Según el Comité mixto FAO/OMS (1970) los antibióticos deben emplearse de forma que no se detecten residuos en los alimentos para consumo humano; y el Código alimentario español prohíbe la venta y utilización de alimentos con antibióticos. El nivel de contaminación por sustancias inhibidoras inespecíficas es alarmantemente alto ya que el 32"62 p. 100 de las muestras de leche analizadas lo contenían. La penicilina se ha detectado en el 1"19 p. 100 de las muestras, la estreptomicina en el 1"11 p. 100, las tetraciclinas en el 1"04 p. 100, la bacitracina en el 9"8 p. 100, la kanamicina en el 0"30 p. 100 y la neomicina en el 1"04 p. 100. De las 1346 muestras de leche analizadas, el 11"66 p. 100 contenían uño o más antibióticos. En la provincia de Córdoba el 25"87 p. 100 dulas
- Published
- 2010
24. Neurofilament ELISA validation.
- Author
-
Petzold, A., Altintas, A., Andreoni, L., Bartos, A., Berthele, A., Blankenstein, M.A., Buee, L., Castellazzi, M., Cepok, S., Comabella, M., Constantinescu, C.S., Deisenhammer, F., Deniz, G., Erten, G., Espino, M., Fainardi, E., Franciotta, D., Freedman, M.S., Giedraitis, V., Gilhus, N.E., Giovannoni, G., Glabinski, A., Grieb, P., Hartung, H.P., Hemmer, B., Herukka, S.K., Hintzen, R., Ingelsson, M., Jackson, S., Jacobsen, S., Jafari, N., Jalosinski, M., Jarius, S., Kapaki, E., Kieseier, B.C., Koel-Simmelink, M.J., Kornhuber, J., Kuhle, J., Kurzepa, J., Lalive, P.H., Lannfelt, L., Lehmensiek, V., Lewczuk, P., Livrea, P., Marnetto, F., Martino, D., Menge, T., Norgren, N., Papuc, E., Paraskevas, G.P., Pirttilä, T., Rajda, C., Rejdak, K., Ricny, J., Ripova, D., Rosengren, L., Ruggieri, M., Schraen, S., Shaw, G., Sindic, C., Siva, A., Stigbrand, T., Stonebridge, I., Topcular, B., Trojano, M., Tumani, H., Twaalfhoven, H.A., Vecsei, L., Pesch, V. Van, Vanderstichele, H., Vedeler, C., Verbeek, M.M., Villar, L.M., Weissert, R., Wildemann, B., Yang, C., Yao, K., Teunissen, C.E., Petzold, A., Altintas, A., Andreoni, L., Bartos, A., Berthele, A., Blankenstein, M.A., Buee, L., Castellazzi, M., Cepok, S., Comabella, M., Constantinescu, C.S., Deisenhammer, F., Deniz, G., Erten, G., Espino, M., Fainardi, E., Franciotta, D., Freedman, M.S., Giedraitis, V., Gilhus, N.E., Giovannoni, G., Glabinski, A., Grieb, P., Hartung, H.P., Hemmer, B., Herukka, S.K., Hintzen, R., Ingelsson, M., Jackson, S., Jacobsen, S., Jafari, N., Jalosinski, M., Jarius, S., Kapaki, E., Kieseier, B.C., Koel-Simmelink, M.J., Kornhuber, J., Kuhle, J., Kurzepa, J., Lalive, P.H., Lannfelt, L., Lehmensiek, V., Lewczuk, P., Livrea, P., Marnetto, F., Martino, D., Menge, T., Norgren, N., Papuc, E., Paraskevas, G.P., Pirttilä, T., Rajda, C., Rejdak, K., Ricny, J., Ripova, D., Rosengren, L., Ruggieri, M., Schraen, S., Shaw, G., Sindic, C., Siva, A., Stigbrand, T., Stonebridge, I., Topcular, B., Trojano, M., Tumani, H., Twaalfhoven, H.A., Vecsei, L., Pesch, V. Van, Vanderstichele, H., Vedeler, C., Verbeek, M.M., Villar, L.M., Weissert, R., Wildemann, B., Yang, C., Yao, K., and Teunissen, C.E.
- Abstract
Contains fulltext : 89601.pdf (publisher's version ) (Closed access), BACKGROUND: Neurofilament proteins (Nf) are highly specific biomarkers for neuronal death and axonal degeneration. As these markers become more widely used, an inter-laboratory validation study is required to identify assay criteria for high quality performance. METHODS: The UmanDiagnostics NF-light (R)enzyme-linked immunoabsorbent assays (ELISA) for the neurofilament light chain (NfL, 68kDa) was used to test the intra-assay and inter-laboratory coefficient of variation (CV) between 35 laboratories worldwide on 15 cerebrospinal fluid (CSF) samples. Critical factors, such as sample transport and storage, analytical delays, reaction temperature and time, the laboratories' accuracy and preparation of standards were documented and used for the statistical analyses. RESULTS: The intra-laboratory CV averaged 3.3% and the inter-laboratory CV 59%. The results from the test laboratories correlated with those from the reference laboratory (R=0.60, p<0.0001). Correcting for critical factors improved the strength of the correlation. Differences in the accuracy of standard preparation were identified as the most critical factor. Correcting for the error introduced by variation in the protein standards improved the correlation to R=0.98, p<0.0001 with an averaged inter-laboratory CV of 14%. The corrected overall inter-rater agreement was subtantial (0.6) according to Fleiss' multi-rater kappa and Gwet's AC1 statistics. CONCLUSION: This multi-center validation study identified the lack of preparation of accurate and consistent protein standards as the main reason for a poor inter-laboratory CV. This issue is also relevant to other protein biomarkers based on this type of assay and will need to be solved in order to achieve an acceptable level of analytical accuracy. The raw data of this study is available online.
- Published
- 2010
25. Simultaneous detection of hepatitis c virus antigen and antibodies in dried blood spots
- Author
-
Brandão, C.P.U., primary, Marques, B.L.C., additional, Marques, V.A., additional, Villela-Nogueira, C.A., additional, Do Ó, K.M.R., additional, de Paula, M.T., additional, Lewis-Ximenez, L.L., additional, Lampe, E., additional, Sá Ferreira, J.A., additional, and Villar, L.M., additional
- Published
- 2013
- Full Text
- View/download PDF
26. 507 SIMULTANEOUS DETECTION OF HEPATITIS C VIRUS ANTIGEN AND ANTIBODIES USING DRIED BLOOD SPOTS SAMPLES
- Author
-
Villar, L.M., primary, Brandao, C.P.U., additional, Marques, B.L.C., additional, da Silva, E.F., additional, Marques, V.A., additional, Villela-Nogueira, C.A., additional, do Ó, K.M.R., additional, de Paula, M.T., additional, Lewis-Ximenez, L.L., additional, Ferreira, J.A. Sá, additional, and Lampe, E., additional
- Published
- 2013
- Full Text
- View/download PDF
27. 990 HEPATITIS A VIRUS (HAV) IMMUNITY AMONG NON INJECTING DRUG USERS: VACCINATION SHOULD BE RECOMMENDED IN DEVELOPING COUNTRIES?
- Author
-
Villar, L.M., primary, Bastos, F.I., additional, Bertoni, N., additional, de Andrade, T.M., additional, Leal, E.M., additional, and Cruz, M.S., additional
- Published
- 2013
- Full Text
- View/download PDF
28. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults
- Author
-
Potsch, D.V., primary, Camacho, L.A.B., additional, Tuboi, S., additional, Villar, L.M., additional, Miguel, J.C., additional, Ginuíno, C., additional, Silva, E.F., additional, Mendonça, R.M.M., additional, Moreira, R.B., additional, and Barroso, P.F., additional
- Published
- 2012
- Full Text
- View/download PDF
29. Dried blood spot samples: Optimization of commercial EIAs for hepatitis C antibody detection and stability under different storage conditions
- Author
-
Marques, B.L.C., primary, Brandão, C.U., additional, Silva, E.F., additional, Marques, V.A., additional, Villela‐Nogueira, C.A., additional, Do Ó, K.M.R., additional, de Paula, M.T., additional, Lewis‐Ximenez, L.L., additional, Lampe, E., additional, and Villar, L.M., additional
- Published
- 2012
- Full Text
- View/download PDF
30. 157 CAN RAPID TESTS BE APPLIED FOR HEPATITIS C VIRUS DIAGNOSIS IN DEVELOPING COUNTRIES?
- Author
-
Villar, L.M., primary, Cruz, H.M., additional, Scalioni, L.P., additional, de Paula, V.S., additional, Miguel, J.C., additional, da Silva, E.F., additional, Oliveira, J.C., additional, Marques, V.A., additional, Portilho, M.M., additional, Marques, B.L.C., additional, Villela-Nogueira, C.A., additional, Milagres, F.A.P., additional, Lewis-Ximenez, L.L., additional, and Lampe, E., additional
- Published
- 2012
- Full Text
- View/download PDF
31. 158 USEFULNESS OF RAPID TESTS FOR HEPATITIS B AND C VIRUS MARKERS DETECTION AMONG CRACK USERS LOCATED AT TWO BRAZILIAN GEOGRAPHICAL AREAS
- Author
-
Villar, L.M., primary, da Silva, E.F., additional, Miguel, J.C., additional, Cruz, H.M., additional, de Oliveira, J.C., additional, Scalioni, L.P., additional, Pereira, R.M., additional, Cruz, M.S., additional, Andrade, T.M., additional, Bastos, F.I., additional, dos Reis, N.B., additional, and Lampe, E., additional
- Published
- 2012
- Full Text
- View/download PDF
32. Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice
- Author
-
Abraira, V., primary, Alvarez-Cermeño, J.C., additional, Arroyo, R., additional, Cámara, C., additional, Casanova, B., additional, Cubillo, S., additional, de Andrés, C., additional, Espejo, C., additional, Fernández, O., additional, Ferrer, J., additional, Figueredo, M.A., additional, García-Merino, A., additional, García-Sánchez, M.I., additional, García-Trujillo, J.A., additional, Gómez, M., additional, González-Oria, C., additional, Gosis, A., additional, Izquierdo, G., additional, Jímenez, J., additional, López-Trascasa, M., additional, Montalbán, X., additional, Moreno, M.J., additional, Muñoz, D., additional, Nuñez, V., additional, Muriel, A., additional, Navarro, J., additional, Olascoaga, J., additional, Oreja-Guevara, C., additional, Prada, A., additional, Ramil, E., additional, Ramo-Tello, C., additional, Rodríguez, C., additional, Rodríguez, E., additional, Rodríguez-Frías, F., additional, Rodríguez-Antigüedad, A., additional, Rodríguez-Molina, J.J., additional, Ruiz, E., additional, Saiz, A., additional, Sarasola, E., additional, Simó, M., additional, Yagüe, J., additional, and Villar, L.M., additional
- Published
- 2011
- Full Text
- View/download PDF
33. 634 SALIVA AS A SOURCE FOR HEPATITIS B VIRUS DIAGNOSIS
- Author
-
Villar, L.M., primary, Medina, H., additional, Villela-Nogueira, C.A., additional, Nabuco, L.C., additional, Rodrigues do Ó, K.M., additional, da Silva, E.F., additional, Lewis-Ximenez, L.L., additional, Yoshida, C.F.T., additional, and Lampe, E., additional
- Published
- 2010
- Full Text
- View/download PDF
34. 635 USEFULNESS OF DRIED BLOOD SPOTS FOR HEPATITIS B VIRUS DIAGNOSIS
- Author
-
Villar, L.M., primary, de Oliveira, J.C., additional, Medina, H., additional, Yoshida, C.F.T., additional, Lampe, E., additional, and Lewis-Ximenez, L.L., additional
- Published
- 2010
- Full Text
- View/download PDF
35. Molecular detection of hepatitis A virus in urban sewage in Rio de Janeiro, Brazil
- Author
-
Villar, L.M., primary, de Paula, V.S., additional, Diniz-Mendes, L., additional, Guimarães, F.R., additional, Ferreira, F.F.M., additional, Shubo, T.C., additional, Miagostovich, M.P., additional, Lampe, E., additional, and Gaspar, A.M.C., additional
- Published
- 2007
- Full Text
- View/download PDF
36. Co-circulation of genotypes IA and IB of hepatitis A virus in Northeast Brazil
- Author
-
Villar, L.M., primary, Morais, L.M., additional, Aloise, R., additional, Melo, M.M.M., additional, Calado, I.A., additional, Lampe, E., additional, and Gaspar, A.M.C., additional
- Published
- 2006
- Full Text
- View/download PDF
37. P.314 Hepatitis A virus in environmental water samples from Amazon Basin
- Author
-
De Paula, V.S., primary, Diniz-Mendes, L., additional, Villar, L.M., additional, Luz, S.B., additional, and Gaspar, A.C., additional
- Published
- 2006
- Full Text
- View/download PDF
38. T05-P-004 ASsociation between C-Reactive protein and metabolic/haemodynamic parameters
- Author
-
Saban-Ruiz, J., primary, Bernal, E., additional, Sanchez, O., additional, Sanchez-Largo, E., additional, Ugalde, A., additional, Fernadez, E., additional, Coca, D., additional, Fabregate, R., additional, Villar, L.M., additional, and Marquez, J., additional
- Published
- 2005
- Full Text
- View/download PDF
39. In situ enzyme immunoassay for titration of a Brazilian hepatitis A virus strain (HAF-203)
- Author
-
Villar, L.M., primary, Amado, L.A., additional, and Gaspar, A.M.C., additional
- Published
- 2004
- Full Text
- View/download PDF
40. An ultrasensitive method for the detection of oligoclonal IgG bands
- Author
-
Sádaba, M.C., primary, González Porqué, P., additional, Masjuan, J., additional, Álvarez-Cermeño, J.C., additional, Bootello, A., additional, and Villar, L.M., additional
- Published
- 2004
- Full Text
- View/download PDF
41. A sensitive and reproducible method for the detection of oligoclonal IgM bands
- Author
-
Villar, L.M, primary, González-Porqué, P, additional, Masjuán, J, additional, Alvarez-Cermeño, J.C, additional, Bootello, A, additional, and Keir, G, additional
- Published
- 2001
- Full Text
- View/download PDF
42. An overview of the marine food poisoning in Mexico
- Author
-
Sierra-Beltrán, A.P, primary, Cruz, A, additional, Núñez, E, additional, Del Villar, L.M, additional, Cerecero, J, additional, and Ochoa, J.L, additional
- Published
- 1998
- Full Text
- View/download PDF
43. Biochemical characterization of human Class I histocompatibility antigens
- Author
-
Escolano, J.M., primary, González-Porqué, P., additional, Roldán, E., additional, Moreno, A., additional, Alvarez-Cermeño, J.C., additional, Bootello, A., additional, and Villar, L.M., additional
- Published
- 1997
- Full Text
- View/download PDF
44. Description of a Solid Phase Enzymoassay for the Detection of Reverse Transcriptase, DNA Polymerase, and Deoxyribonuclease
- Author
-
Nocito, M., primary, Villar, L.M., additional, and Gonzalezporque, P., additional
- Published
- 1993
- Full Text
- View/download PDF
45. Soluble Class I Antigen Secretion by Peripheral Blood Lymphocytes in Multiple Sclerosis
- Author
-
Alvarez-Cermeño, J.C., primary, Brieva, J.A., additional, Villar, L.M., additional, Roldán, E., additional, Bootello, A., additional, and González-Porqué, P., additional
- Published
- 1993
- Full Text
- View/download PDF
46. Intrathecal synthesis of soluble class I antigens in multiple sclerosis
- Author
-
Alvarez-Cermeño, J.C., primary, Villar, L.M., additional, Nocito, M., additional, Bootello, A., additional, and González-Porqué, P., additional
- Published
- 1992
- Full Text
- View/download PDF
47. Purification and properties of membrane and cytosolic phosphatidylinositol-specific phospholipases C from human spleen
- Author
-
Roy, G., primary, Villar, L.M., additional, Lazaro, I., additional, Gonzalez, M., additional, Bootello, A., additional, and Gonzalez-Porque, P., additional
- Published
- 1991
- Full Text
- View/download PDF
48. Intrathecal synthesis of soluble class I antigens (sHLA) in patients with HIV infection and tuberculous meningitis
- Author
-
Alvarez-Cermen˜o, J.C., primary, Varela, J.M., additional, Villar, L.M., additional, Casado, C., additional, Dominguez, M., additional, Roy, G., additional, Bootello, A., additional, and Gonzalez-Porque, P., additional
- Published
- 1990
- Full Text
- View/download PDF
49. The expression of integrins on activated T-cells in multiple sclerosis. Effect of intravenous methylprednisolone treatment.
- Author
-
Luján, S., Masjuan, J., Roldán, E., Villar, L.M., González-Porqué, P., and Álvarez-Cermeño, J.C.
- Subjects
DRUGS ,LYMPHOCYTES ,MULTIPLE sclerosis ,CELL adhesion molecules ,INTEGRINS - Abstract
We studied the effect of intravenous methylprednisolone (MP) on the expression of the integrins, LFA-1 and VLA-4, on activated blood T-lymphocytes in 17 patients with relapses of clinically definite relapsing-remitting MS. MP treatment did not induce changes in the expression of CD3, CD4, DR, LFA-1 or VLA-4 markers when measured in the total population of lymphocytes in MS patients in relation to treatment. Treatment influenced neither the LFA-1 nor VLA-4 positive cells within the CD3+ population. MP treatment clearly decreased the DR+ CD3+ cells (P<0.01) and the percentage of DR+ CD3+ lymphocytes bearing VLA-4 (P<0.01). However, this was not the case when we studied the percentage of lymphocytes which expressed LFA-1. Glucocorticoids did not influence the mean intensity of the expression of the two integrins quantified in either total or DR+ CD3+ lymphocytes. Although, further research seems warranted to investigate a possible effect of MP on lymphocyte integrin function, this work corroborates the idea that MP treatment may interfere with the mechanisms of T-cell migration into CNS, thus modulating the activity of multiple sclerosis. [ABSTRACT FROM AUTHOR]
- Published
- 1998
50. Implication of soluble and membrane HLA class I and serum IL-10 in liver graft acceptance - effects on liver, infection rate, and outcome
- Author
-
Minguela, A., Toro, A., Marn, L., Muro, M., Villar, L.M., Daz, J., Ramrez, P., Parrilla, P., Garca-Alonso, A.M., and Alvarez-Lopez, M.R.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.